Quote:

---

Australian of the Year Richard Scolyer 'blown away' by success of radical new brain cancer treatment

Professor Scolyer, 57, was diagnosed with glioblastoma IDH wild-type in early June last year and became "patient zero" in a pioneering immunotherapy approach that has produced remarkable results: the tumour has not come back after 10 months.

So, how does it work? Professor Long targeted Professor Scolyer's specific brain tumour with a unique combination immunotherapy that was applied for 12 days before surgery. Professor Scolyer then underwent brain surgery to remove as much of the tumour as possible. He received radiation after the operation and continues to receive immunotherapy and a personalised vaccine.
https://www.abc.net.au/news/2024-04-01/richar.../103610270

---

He might be even more blown away if he knew about leronlimab.

I was wondering what immunotherapy he was using and I knew it was related to his melanoma research. Most likely it was a CTLA-4 inhibitor and a PD-1 inhibitor. Leronlimab downregulates CTLA-4 and PD-L1 the ligand for PD-1 and more.

Leronlimab's MOAs for cancer - Leronlimab elicits an NKT cell response - promoting tumor cell death , upregulates CD8+ T cells, Inhibits angiogenesis, shuts down cancer reappearing through collagen downregulation, Stops the recruitment of Tregs to tumor sites (Tregs promote tumor immunity), inhibits tumor cell dna repair via GRP78 downregulation, inhibits IL-13 a tumor protectant, downregulates IL-4 (IL-4 promotes tumor immunity), upregulates IFN-gamma promoting tumor cell death, downregulates PD-L1 the ligand for the PD-1 receptor, polarization of macrophages - promoting tumor cell death , downregulates CTLA-4, downregulates calcium channel signaling, blocks CCL5 shutting down pathways for CTCs.